Evaluating the Role of Ruxolitinib as Treatment of Graft-Versus-Host Disease
Tania Jain, MBBS, discusses the role of ruxolitinib as treatment of graft-versus-host disease.
Tania Jain, MBBS, assistant professor at Johns Hopkins University, discusses the role of ruxolitinib (Jakafi) as treatment of graft-versus-host disease (GVHD).
At her institution, she has used ruxolitinib as treatment of GVHD for patients with grade 2 through 4 disease. However, because of the biology of GVHD, responses are observed more frequently in patients with grade 2 versus grades 3 and 4 GVHD. This is consistent with data that has been observed in the REACH-1 and REACH-2 clinical trials.
Although there are responses with ruxolitinib, physicians should be wary of potential infections or cytopenias, Jain says. Physicians should keep these concerns in mind as they use the agent.
Tucatinib Plus T-DM1 Improves PFS in Previously Treated HER2+ Metastatic Breast Cancer
December 6th 2023The introduction of tucatinib to ado-trastuzumab emtansine significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer.
Read More
Pembrolizumab/Olaparib Did Not Improve Survival in Locally Advanced or Metastatic TNBC
December 6th 2023Maintenance pembrolizumab plus olaparib did not improve progression-free or overall survival in patients with locally recurrent inoperable or metastatic triple-negative breast cancer.
Read More
Neoadjuvant Chemo/Pembro Betters pCR in Key ER+ Breast Cancer Subgroups
December 6th 2023Adding pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab with endocrine therapy demonstrated improvements pathologic complete responses in key subsets of patients with early-stage, high-risk, estrogen receptor–positive/HER2-negative breast cancer.
Read More
ctDNA May Identify Risk of Recurrence in Early Breast Cancer Subgroup
December 6th 2023Patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer given abemaciclib for 2 years in addition to endocrine therapy demonstrated an association between ctDNA positivity and disease recurrence.
Read More
Capivasertib Shows Superior PROs Vs Placebo in HR+, HER2- Breast Cancer
December 6th 2023Patient-reported outcomes of the CAPItello-291 study of capivasertib plus fulvestrant showed a positive benefit-risk profile for the combination in patients with HR-positive, HER2-negative advanced breast cancer.
Read More
